...tolerability of ACI-91 was rated as "good" in most patients. AC Immune in-licensed ACI-91 from ProteoSys...
...of crenezumab to treat AD are expected in 2014. AC Immune S.A. , Lausanne, Switzerland ProteoSys AG...

...that are involved in cognition and memory. In 2005, researchers at biomarker company ProteoSys AG (now ProteoSys...
...domain of the protein's beta-1 isoform - had potential neuroprotective effects on the CNS. Because ProteoSys...
...Remy Luthringer, who suggested testing the neuroprotective properties of the fragment in models of PD. ProteoSys...

...to IP covering the biomarker annexin A3 (ANXA3) to develop a diagnostic for prostate cancer. ProteoSys...
...upfront payment and is eligible for milestones and royalties. bioMerieux S.A. (Euronext:BIM), Marcy l'Etoile, France ProteoSys...

...AG (Munich); Lion bioscience AG (NMarkt:LIO; LEON, Heidelberg); MTM Laboratories AG (Heidelberg); Nanotype GmbH (Graefelfing); ProteoSys AG...